Compare JPMorgan Chase & Co (JPM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs BIO-TECHNE Corp — how do they compare? JPMorgan Chase & Co trades at $362.35 (market cap $956.39B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: JPMorgan Chase & Co is far larger — about 85.1× BIO-TECHNE Corp's market cap, and JPMorgan Chase & Co pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| JPM | TECH | |
|---|---|---|
Market Cap | $956.39B | $11.24B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $359.79 | $72.29 |
52-Week Low | $282.84 | $43.31 |
Dividend Yield | 1.67% | 0.44% |
Enterprise Value | — | $11.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $362.04, up 1.26% today, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, with net income margin at 33.38% and ROE of 18.43%. The stock shows robust fundamentals, including a P/E of 15.42 and consensus price target of $374.18. Cash flow trends indicate significant financing activities, while geopolitical and cybersecurity risks are noted in recent news.
The outlook for JPM remains positive, driven by earnings momentum and institutional confidence. Key risks include macroeconomic volatility and regulatory challenges. With a moderate buy consensus and strong profitability metrics, the stock presents a solid opportunity for growth-oriented investors, though vigilance on external risks is warranted.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
